Finch Therapeutics Group, Inc. FNCHQ
10.35
0.00
0.00%
as of 24 Sep
- Market cap
- $1.6M
- P/E
- 0.0×
Follow FNCHQ
Growth Flags
show if company had growth for consecutive years
| Older periods | Sep '23 | Dec '23 | Mar '24 | Jun '24 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(134.61%) | (126.06%) | (62.64%) | (67.28%) | |
| (79.79%) | (68.48%) | (25.22%) | (25.20%) | ||
ROIC |
(259.33%) | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(384.47%) | (334.37%) | (89.33%) | (106.33%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(25.45) | (18.80) | (14.00) | (11.24) | |
Free Cash Flow |
(40.85) | (30.18) | (22.49) | (18.05) | |
Capital Expenditures |
1.23 | 1.33 | — | — | |
Piotroski F-Score |
1.00 | — | — | — | |
| Other line items | |||||
Cash ROIC |
(50.45%) | (65.62%) | (56.50%) | (59.68%) | |
Accounts Payable Turnover |
4.07 | 0.00 | 0.00 | 0.00 | |
Inventory Turnover |
0.00 | — | — | — | |
Average Days of Payables |
45.18 | 0.00 | 0.00 | 0.00 | |
Days of Inventory on Hand |
0.00 | — | — | — | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
— | 0.00% | — | — | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.43 | 0.42 | 1.38 | 1.27 | |
Depreciation/Fixed assets |
4.53 | 2.56 | 0.36 | 0.36 | |
Capex/Depreciation |
0.42 | 0.87 | 0.00 | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(26.21) | (19.63) | (14.00) | (11.24) | |
Capex per Share |
0.76 | 0.83 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | — | — | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates